

17 **Abstract**

18 Influenza A has two main clades, with stronger cross-immunity to reinfection within than be-
19 tween clades. Here, we explore the implications of this heterogeneity for proposed cross-protective
20 influenza vaccines that may offer broad, but not universal, protection. While the development
21 goal for the breadth of human influenza A vaccine is to provide cross-clade protection, vaccines in
22 current development stages may provide better protection against target clades than non-target
23 clades. To evaluate vaccine formulation and strategies, we propose a novel perspective: a vaccine
24 population-level target product profile (PTPP). Under this perspective, we use dynamical mod-
25 els to quantify the epidemiological impacts of future influenza A vaccines as a function of their
26 properties. Our results show that the interplay of natural and vaccine-induced immunity could
27 strongly affect seasonal clade dynamics. A broadly protective bivalent vaccine could lower the
28 incidence of both clades and achieve elimination with sufficient vaccination coverage. However,
29 a univalent vaccine at low vaccination rates could permit a resurgence of the non-target clade
30 when the vaccine provides weaker immunity than natural infection. Moreover, as a proxy for
31 pandemic simulation, we analyze the invasion of a variant that evades natural immunity. We find
32 that a future vaccine providing sufficiently broad and long-lived cross-clade protection at a suffi-
33 ciently high vaccination rate, could prevent pandemic emergence and lower the pandemic burden.
34 This study highlights that as well as effectiveness, breadth and duration should be considered in
35 epidemiologically informed TPPs for future human influenza A vaccines.

36 **Keywords:** Human influenza A; Vaccine; Dynamic model; Cross immunity; Immuno-epidemiology

1 Introduction

Seasonal epidemics and occasional pandemics of human influenza A viruses cause substantial public health burden. Although vaccination is an important approach to mitigate this burden [3], current influenza A vaccines have significant limitations. First, they need to be evaluated annually for updates, due to the rapid turnover of antigenic variants. Second, existing vaccines can have low efficacy and narrow specificity (therefore cannot pre-emptively target potential pandemic influenza variants [14, 24, 15]). In addition, the frequent update of current vaccines may worsen vaccine hesitancy of individuals and increase the economic burden of vaccine purchases [2]. To tackle this challenge, there have been great efforts to develop a new generation of broadly-protective influenza vaccines [16, 22, 17, 1, 15]. However, there remain challenges in establishing broad protection. For example, a vaccine that targets one clade (e.g., clade 1) of human influenza A by raising stem-targeted antibodies might provide limited cross-protection to the other clade (e.g., clade 2) [17]. Widespread use of such a vaccine could have complex effects on influenza epidemiology where both clade 1 and 2 are already endemic, in ways that are not yet fully understood.

Here we construct a compartmental model to quantify vaccine impacts on seasonal influenza dynamics and potential pandemic invasions. The model incorporates host immunological history and clade co-existence. We model cross-clade interactions using H1N1 and H3N2 as respective representatives of H1 and H3 clades, choosing model parameters to match the broad behaviour of human influenza A in the USA in recent seasons. We assume the vaccine provides clade-level protection, i.e., strong cross-protection within one clade of influenza A but weaker cross-protection between clades. We focus on the impact of vaccinal immunity strength and duration on 1) seasonal strain dynamics of endemic infections and 2) immune escape at inter- and intra-clade levels, mimicking pandemic emergence. We can frame these variables by extending the standard notion of the Target Product Profile (TPP), which typically focuses on vaccine benefits to the individual, such as effectiveness. Although the TPP is an essential tool, we argue that its value for future influenza vaccines could be strengthened by considering the population-level processes (beyond vaccine effectiveness) more explicitly.

2 Methods

2.1 Mathematical model

When modelling human influenza strain dynamics, incorporating sufficient antigenic variation comes at the cost of complex host immune history. History-based models [27] take the host view, to track host infection history by different strains without including large variations in antigenicity. In contrast, while not including host immune history, status-based models [12] take the pathogen view, to track their impacts on hosts' future infections by all other strains. To balance the complexity of antigenic variation and host immune history, we focus on the clade level of the influenza A virus phenotype and include relevant host immune history. We use $i = 1$ and $i = 2$ to represent the 'H1' and

73 'H3' clades, respectively. We construct our model (Figure 1), based on a previous 2-strain SIRS
 74 model on pertussis [19, 20] that incorporates host immune history. Our model allows immunity to
 75 reduce susceptibility against subsequent infections, and we refer to the proportional reduction in
 76 susceptibility as the *strength of cross-immunity* (using θ for infection-induced immunity, and τ for
 77 vaccine-induced immunity).

78 Hosts acquire immunity either via natural infection or vaccination. In the example of H1, we
 79 define transmission rate as β_1 . Following natural infection, strain-transcending immunity is induced
 80 first, i.e., short-term immunity against all clades, which can potentially shape the genetic diversity
 81 of seasonal human influenza [10]. This immunity wanes at rate σ_T . After it wanes, the host can get
 82 infected by another clade with reduced susceptibility ($\beta_2(1 - \theta_1)$); or immunity can further wane (at
 83 rate σ_1), making the host fully susceptible to infections from both clades. After the host is infected
 84 with both clades, they are fully protected against all infections until immunity wanes. This immunity
 85 can wane (at rate σ_2), making the host susceptible to the second clade again.

86 Hosts acquire vaccinal immunity via vaccination at rate ρ . This immunity wanes at rate σ_V . We
 87 assume that vaccinal immunity can further enhance infection-induced immunity, and the resulting
 88 cross-immunity is modelled as a product of infection and vaccinal immunity. For example, a host
 89 recovered from H1 primary infection who is vaccinated has reduced susceptibility against H3 of
 90 $\beta_2(1 - \theta_1)(1 - \tau_1)$. We ignore the vaccine's boosting effect on homotypic immunity when the host has
 91 already acquired 'perfect' immunity (100% susceptibility reduction) against the clade via infection.

92 Regarding vaccine breadth, we model the following three vaccine scenarios:

- 93 • Bivalent vaccine. The vaccine reduces susceptibility against both clades proportionally by τ_1 and
 94 τ_2 , respectively. The duration of vaccinal immunity is $\frac{1}{\sigma_V}$. The vaccination rate is $\rho_1 = \rho_2 = \rho$.
 95 A bivalent vaccine is the ultimate goal of broadly-protective vaccine development; however,
 96 during initial development stages, it is likely that the vaccines would be univalent [17]:
- 97 • Univalent H1 vaccine. The vaccine fully reduces susceptibility against H1 clade ($\tau_2 = 1$) and
 98 partially against H3 clade ($\tau_1 < 1$). The duration of the immunity is $\frac{1}{\sigma_V} = \frac{1}{\sigma_{V_1}}$; the vaccination
 99 rate is $\rho = \rho_1$.
- 100 • Univalent H3 vaccine. The vaccine fully reduces susceptibility against H3 clade ($\tau_1 = 1$) and
 101 partially against H1 clade ($\tau_2 < 1$). The duration of the immunity is $\frac{1}{\sigma_V} = \frac{1}{\sigma_{V_2}}$. The vaccination
 102 rate is $\rho = \rho_2$.

103 In each scenario, the strength and duration of the vaccinal immunity is same as that of infection-
 104 induced immunity ($k_1 = \frac{\tau_{1,2}}{\theta_{1,2}} = 1, k_2 = \frac{\sigma_{1,2}}{\sigma_{V_{1,2}}} = 1$). In further analysis, we vary k_1 or k_2 to be 0.5 or
 105 2 to explore the vaccine's impacts on seasonal epidemics (Figure 2 and 3).

106 In addition, our model is *seasonally forced* because seasonality is a frequent characteristic of non-
 107 pandemic human influenza incidence [6]. The transmission rate $\beta_1(t)$ and $\beta_2(t)$ is determined by a
 108 standard sinusoidal function [9, 7]:

$$\beta_i(t) = R_0^{(i)}(\gamma_i + \mu)(1 + a \cos(2\pi t)) \quad (1)$$

109 where $i = 1, 2$ represents H1 or H3 clade, $R_0^{(i)}$ is the basic reproductive number of the clade i , γ is
 110 the recovery rate, μ is the birth rate and a is amplitude of the sinusoidal forcing. All parameters in
 111 the model and the sources of their values are listed in Table S2.

112 The model (Figure 1) is described by the ordinary differential equations in Supplementary ma-
 113 terials S1.2. We set the initial conditions by assuming a 0.1% prevalence for H1 and H3 infections
 114 separately (therefore 0.2% in total). We assume that the remaining 99.8% of the population is fully
 115 susceptible. We then run deterministic simulations by numerically integrating the model for 100 years
 116 at semiweekly time steps to allow the system to reach its endemic phase. Subsequent analyses are
 117 based on this endemic phase reached from the initial condition. Sensitivity tests show that different
 118 initial conditions would have negligible effect on our results (Figure S1 and S2).




Figure 1: Model diagram. Births and deaths at rate μ per capita are not shown. The dashed lines show waning of immunity. The solid lines show infection, vaccination, or recovery. Each squared compartment can have up to four equal-sized 'sub-squares' representing infection or immunity status. The left top sub-square represents primary infection; the right top is secondary infection. The infection is either of H1 clade (pink) or H3 clade (blue). The bottom two sub-squares denote strain-transcending immunity (yellow) and vaccinal immunity (green). Definitions of all compartments are in Table S1 and all parameters in Table S2. The ordinary differential equations of the model are in Supplementary S1.2

119 2.2 Model calibration

120 To ensure that the model captures subtype dynamics broadly consistent with that observed in temper-
 121 ate regions, we use influenza surveillance data during the 2004/2005-2018/2019 seasons in the USA.

122 We use data on subtypes H1N1 and H3N2 to represent H1 and H3 clades. We omit the pandemic
 123 period (2008-2009, 2009-2010 and 2010-2011 seasons), shown as grey area in Figure S3. In order
 124 to capture broad features of influenza A epidemiology in the USA, we match model simulations to
 125 summary statistics of human influenza A incidence rates in the USA (Figure S3) as listed below: the
 126 auto-correlation and coefficient of variation of subtype incidence and cross-correlation between sub-
 127 type incidence. Key transmission parameters (Table S2) are drawn from a previous human influenza
 128 disease-dynamic modeling study focusing on Hong Kong [26].

129 The incidence rate (Figure S3) is estimated by combining influenza-like illness (ILI) surveillance
 130 data and laboratory-confirmed subtyping data as in the equation below, which is adapted from a
 131 previous study [8].

132 *Weekly incidence rate of subtype x = Outpatient ratio (Ratio of ILI patients among all hospital*
 133 *visits) * Ratio of influenza positive sample among all testings * Ratio of subtype x among all positive*
 134 *samples*

135 where $x = \text{H1N1}$ or H3N2 , and we used the ILI surveillance data weighted by the state population.
 136 Outpatient illness surveillance data and viral surveillance data were downloaded from FluView (US
 137 Centers for Disease Control and Prevention, CDC [11]). Viral surveillance data were collected from
 138 the US World Health Organization (WHO) Collaborating Laboratories and National Respiratory and
 139 Enteric Virus Surveillance System (NREVSS) laboratories [23].

140 Given the crudeness of the available data, we do not aim to capture detailed incidence in each
 141 season. Instead, we aim to match high-level patterns in the data, particularly in relation to the
 142 dominance patterns of the subtypes through time. We adjust values of three parameters: infection-
 143 induced cross-immunity strength (θ_1 and θ_2) and amplitude of sinusoidal seasonal forcing function
 144 (a) (to adjust the incidence). The incidence at each time step is calculated as the new infections
 145 with the focal clade regardless of the hosts' immune statuses. The optimization metric is the sum
 146 of the absolute distance between simulation and data [11] of three summary statistics, including I)
 147 correlation between H1 and H3 seasonal incidence, II) coefficient of variation of H1 (and H3) seasonal
 148 incidence, III) auto-correlation of H1 (and H3) seasonal incidence. We run deterministic simulations
 149 by numerically integrating the model for 2000 years at semi-weekly time steps. We then calculated
 150 the statistics for every 12-year period (the first 800 years were removed as burn-in) and obtained a
 151 distribution of summary statistics. The optimization metric distribution across the parameter space
 152 (Figure S4) shows that when the seasonal forcing is weak, i.e., $a = 0.04$, the distances between
 153 simulation and data are the smallest, which is consistent with previous studies [9, 7]. For further
 154 analysis, we use the best parameter set $\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$ that gives the minimal distance
 155 across the parameter space (Figure S5). For sensitivity test, we choose a moderately-fit parameter set
 156 $\theta_1 = 0.55, \theta_2 = 0.35, a = 0.04$ that is more common across different a than other parameters (Figure
 157 S6). The results show that both parameter sets well match the dominance patterns of the subtypes
 158 in the data (Figure S7 and S8).

2.3 Invasion analysis of antigenic variants

To test the impact of the strength and duration of vaccinal immunity on pandemic emergence, we model a scenario where the population is exposed to (for simplicity) only one clade and is vaccinated against this clade. We simulate the model for 600 years at semi-weekly time steps to reach the endemicity of this clade. Then, a pandemic variant that fully escapes natural immunity is introduced to the population. We explore a range of basic reproduction numbers of the pandemic variant ($R_0^{(1)}$) holding the endemic strain's $R_0^{(2)}$ at 1.6, where i) $R_0^{(1)} = 1$, ii) $1 < R_0^{(1)} < R_0^{(2)}$, iii) $R_0^{(1)} = R_0^{(2)}$, and iv) $R_0^{(1)} = 2R_0^{(2)}$. To test the vaccine impact, we vary the vaccination rate from 0 to 2% per week, the susceptibility reduction of the vaccine against the pandemic variant from 0 to 100% and vaccine immunity duration from 0.5, 1, 2, 4, 8 to 16 years. Using species invasion analysis similar to a previous study [20], we analyze the growth rate of the pandemic variant in the population as shown in the equation S7 (See Supplementary materials S1.3). We then numerically integrate the equations S1 to obtain deterministic dynamics of the system following the introduction of the pandemic variant with an incidence of one-millionth of the population size. The pandemic variant approximately follows exponential growth at the initial stage of invasion; therefore, we quantify the initial growth rate as the difference between the logarithm of the pandemic variant's incidence on the third day and that on the second day, divided by the time difference (1 day). To quantify the persistence of the pandemic variant, we use trough depth, i.e., the minimal incidence of the pandemic variant after its initial peak.

3 Results

3.1 Impacts on seasonal epidemics of vaccinal immunity breadth, strength and duration

For each vaccinal immunity breadth scenario (see Methods), we explore a range of different strengths (Figure 2) and durations of vaccine-induced cross-protection (Figure 3) relative to infection-induced immunity. The robustness of the results is confirmed using not only the best-fitting parameters set, but also alternative, moderately-fitting parameter sets (Figure S9 and S10).

A bivalent vaccine (top row in Figure 2 and 3) would eliminate both clades without the potential of an incidence increase. The vaccination rates required to eliminate H1 and H3 are lower when the vaccinal immunity is stronger or longer. Due to higher R_0 , the H3 clade requires a higher vaccination rate to eliminate. When the vaccine targets one clade (either H1 or H3 clade, bottom two rows in Figure 2), providing the same or weaker immunity than natural infection (the left and middle columns in Figure 2), low vaccination rates could lead to an increase in the incidence of the non-target clade. The peak of the incidence occurs at the vaccination rate that eliminates the target clade. In contrast, when the vaccine-induced cross-immunity is stronger than natural immunity, the incidence of the off-target clade always decreases with the vaccination rate (the right column in Figure 2). The reason for this contrast lies in the interplay of natural and vaccinal cross-immunity:

- When the vaccination rate is 0, the cross-immunity is completely infection-induced.

- 195 • Before the target clade is eliminated, the cross-immunity comprises vaccinal and natural immu-
196 nity that is stronger than vaccinal immunity alone.
- 197 • When the target clade is eliminated, the cross-immunity against the non-target clade is com-
198 pletely vaccine-induced.

199 Therefore, depending on the relative strength of vaccinal and natural immunity, the combined strength
200 of vaccinal and natural cross-immunity becomes either stronger or weaker with the increase in vacci-
201 nation rate.

202 Similarly, when the strength of vaccinal immunity is the same as infection-induced immunity, the
203 H1 or H3 vaccine could eliminate the target clade at a low vaccination rate (bottom two rows in Figure
204 3). However, the incidence of the non-target clade could increase slightly at low vaccination rates. The
205 shorter the duration of vaccine immunity compared to the infection immunity, the higher the minimum
206 vaccination rate required to prevent any incidence increase of non-target clade. Additionally, when
207 vaccine-induced immunity duration is twice as long as infection-induced immunity, the vaccination
208 rate required for eliminating one clade and reaching the incidence plateau of the other clade is
209 correspondingly reduced to 50% (Figure 3).

210 **3.2 Impacts on pandemic emergence and persistence of vaccinal immunity** 211 **breadth, strength and duration**

212 *How might vaccinal cross-immunity strength and duration collectively impact the emergence of a*
213 *pandemic variant in a vaccinated population?* As a simple representation of pandemic emergence,
214 we assume the population is exposed to only one endemic clade, e.g., H3 clade (i.e., $i = 2$), and is
215 vaccinated by the vaccine targeting H3 clade. Then it is exposed to a pandemic variant. We made
216 a pessimistic assumption that H3 infection does not induce cross-immunity against the pandemic
217 variant. The analytical result (Supplementary materials S1.3) shows that even when the pandemic
218 variant has a lower basic reproductive number than the endemic strain, i.e., $R_0^1 < R_0^2$, the pandemic
219 can still emerge in the population, depending on the vaccine characteristics. Results in Figure 4 show
220 how the initial growth rate of the pandemic variant depends on vaccine characteristics, including
221 vaccination rate and immunity strength and duration. First, the boundary of pandemic emergence
222 (shown with the red curve) moves towards less susceptibility reduction by the vaccine, for lower
223 values of R_0^1 (Figure 4). In line with intuition, this indicates that the threshold of vaccine cross-
224 immunity strength to prevent the pandemic is strongly dependent on the basic reproductive number
225 of the pandemic variant. In addition, longer vaccine-induced cross-immunity duration lowers the
226 vaccination rate threshold and vaccinal immunity strength level for preventing pandemic emergence.

227 Following introduction, the pandemic variant can either 1) fail to emerge, 2) emerge and co-exist
228 with the endemic strain, or 3) emerge and eliminate the endemic strain. Under limited vaccinal
229 protection, the endemic and pandemic strains co-exist (corresponding colored areas in Figure 5 and
230 S11 under the same vaccine characteristics). Vaccination characteristics and fitness of the pandemic
231 strain decide the emergence of the pandemic strain (Figure 5 and S12). Any of the following vaccine




Figure 2: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *strengths* (columns, defined as $k_1 = \frac{\tau_i}{\theta_i}$), with changes of vaccination rate (%) per week (x axis). The results are calibrated with the best-fitting parameters ($\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$). Other parameter values are in Table S2




Figure 3: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *durations* (columns, defined as $k_2 = \frac{\sigma_i}{\sigma_V}$), with changes of vaccination rate (%) per week (x axis). The parameters are same as in 2.




Figure 4: Emergence of a pandemic variant with the basic reproduction number R_0^1 (column), which is measured by initial growth rate coloured by greens (failure of emergence) and yellow-to-reds (emergence), under vaccination of different immunity strength (y axis), duration (row) and vaccination rate ρ (%) per week (x axis). In these simulations, the pandemic variant completely escapes natural cross-immunity ($\theta_2 = 0$), the average infection-acquired immunity period is 2.7 years, the average infectious period is 3.03 days, and the average life span is 75 years. The initial growth rate is defined as the incidence growth of the pandemic variant between the second and third day of the invasion.

232 characteristics could more easily prevent the emergence of the pandemic variant: higher vaccination
 233 rate, longer immunity duration and more susceptibility reduction against the pandemic variant (Figure
 234 5). Interestingly, at the same vaccination rate, more susceptibility reduction could increase the
 235 incidence during the trough following invasion (Figure S12). This could be because stronger cross-
 236 immunity against the pandemic variant allows slower spread of the variant at the beginning. Due
 237 to the demographic stochasticity, when the trough depth is lower than 10^{-6} , the pandemic variant
 238 could still become extinct (e.g., Figure S12) in a very large city. Therefore, we define the pandemic
 239 persistence threshold (orange curve in Figure 5) as 10^{-6} . Additionally, the result suggests that the
 240 pandemic invasion trough depth might have a non-monotonic relationship with vaccine strength and
 241 vaccination rate. This non-monotonic relationship on persistence has been shown in other studies
 242 [18].

243 4 Discussion

244 While TPPs of a vaccine are rightly informed by individual-level factors such as safety and efficacy
 245 against a symptomatic endpoint, the population-level epidemiological impacts of vaccines are less
 246 considered. By quantifying the potential epidemiological impacts, our work illustrates how TPPs




Figure 5: Persistence of the pandemic variant 5 years after its emergence, measured by trough depth of its incidence ((the minimal incidence), under vaccination of different immunity strength (y axis), duration (row) and vaccination rate ρ (%) per week (x axis), with different basic reproduction number R_0^1 (column). The grey area is when the pandemic variant fails to emerge. The black curves indicate the transition between persistence and failure in the emergence of the pandemic variant. Other parameters are same as those in Figure 4.

247 could be complemented with population-level effectiveness, breadth, and immunity duration. What
 248 indicators would be important in such population-level TPPs? Based on our analysis, Table 1 lists

249 some important characteristics, as well as some that should be addressed in future studies.

250

Table 1: Population-level Target Product Profiles (PTPPs) for broadly-protective human influenza A vaccines

Vaccine characteristic	Preferred	Study sources
Breadth	Complementary vaccines for all clades (in the absence of universal protection)	This study
Strength*	No weaker than infection-induced immunity	This study
Duration*	No shorter than infection-induced immunity	This study
Immunity type	Susceptibility-reduction (preferred to infectiousness reduction)	This study and [5]
Dose regimen	Annual vaccination	[21]
Vaccination rate	High rate (the sufficient rate depends on the vaccination strategy)	This study
Vaccination acceptability and achievable coverage	/	Future studies
Interaction of vaccine immunity with prior immunity	/	Future studies
Evolutionary impacts on seasonal influenza viruses	/	Future studies building on existing literature ([4])

* In practice, the strength and duration of the vaccine are usually correlated [14].

251 Specifically, our results show how the interplay between natural and vaccine-induced cross-immunity
 252 affects both clade dynamics and pandemic emergence. In this process, both vaccine immunity strength
 253 and cross-immunity strength are important. Notably, when a broadly protective vaccine provides lim-
 254 ited protection against a non-target clade, this clade might cause a larger epidemic at low vaccination
 255 rates, than in the absence of vaccination. In contrast, the bivalent vaccine scenario never permits a
 256 larger epidemic and could eliminate both clades at similar vaccination rates. Therefore, our results
 257 highlight that adopting vaccines for against both clades would be essential for the broadly-protective
 258 vaccine deployments.

259 Additionally, when a vaccine-escape variant emerges, the population might be more vulnerable
 260 to the variant [5] than in the absence of the vaccine. For example, in theory, a vaccine providing
 261 cross-immunity by reducing infectiousness would reduce transmission at the population level and
 262 improve herd immunity in the long term [4]; however, such a vaccine might permit larger pandemics
 263 when the coverage is low [5], by increasing the population’s vulnerability to a pandemic invasion
 264 by a non-target variant. These existing studies focused on hypothesized vaccines that only reduce

265 the infectiousness without reducing the susceptibility to infection, consistent with the effect of non-
266 sterilizing T-cell immunity. Currently, promising vaccine candidates are being developed to reduce
267 susceptibility to infection, e.g., one targeting the HA-stalk region [17]. Our results illustrate the
268 potential of the epidemiological impacts of such vaccines: they might have a lower risk of permitting
269 a larger pandemic than those that reduce infectiousness.

270 However, due to the lack of relevant experimental data on the mechanisms of vaccinal immunity,
271 our results remain theoretical. Other caveats of this work include that the model assumes a homoge-
272 neous infection in a well-mixed population; for example, age or spatial structure of hosts or antigenic
273 imprinting [13] could favor the invasion of the pandemic variant. The model also does not incorpo-
274 rate subtype diversity within clades of influenza viruses, nor does it address the effect of immunity
275 on severity. In addition, we did not assess potential evolutionary impacts of the broadly-protective
276 vaccines [4]. Furthermore, our model calibration only matches the subtype dominance pattern. The
277 model could be refined by fitting time series of influenza incidence in the future, if more refined
278 data become available. Finally, we assume that vaccine-induced and infection-induced immunity are
279 independent, but in practice, they might oppose each other due to a possible ceiling effect, i.e., the
280 level of protection cannot exceed a threshold. Nonetheless, even our simple epidemiological model
281 provides insights into the potential value of population-level TPPs: the importance of considering
282 immunity breadth, strength and duration in broadly-protective vaccine design and deployments. To
283 advance understanding of population-level TPPs, future studies could incorporate virus genomic data
284 and human immune data by applying immuno-epidemiological phylodynamic modelling approaches.
285 These advances depend crucially on maintaining and enhancing epidemiological, genomic, and im-
286 mune surveillance against influenza and other imperfectly-immunizing pathogens.

287 **5 Acknowledgements**

288 This work was funded by FluLab. Q.Y. acknowledges funding from the Center for Health and Wellbe-
289 ing, Princeton University, via Graduate Funding for Health-Focused Research. S.W.P. acknowledges
290 funding from Princeton University via a Charlotte Elizabeth Procter Fellowship. C.M.S.-R. acknowl-
291 edges funding from the Miller Institute for Basic Research in Science of UC Berkeley via a Miller
292 Research Fellowship. B.T.G acknowledges support from Princeton Catalysis Initiative. The authors
293 thank Bin Zhang for suggesting potential datasets. Disclaimer: The findings and conclusions in this
294 report are those of the authors and do not necessarily represent the official position of the US National
295 Institutes of Health or Department of Health and Human Services.

296 **6 Author contributions**

297 N.A. and B.T.G. contributed to funding acquisition and supervision. Q.Y., S.W.P., C.M.S.-R., N.A.,
298 and B.T.G. contributed to model conceptualization. Q.Y. and S.W.P. contributed to formal analysis
299 and visualization. Q.Y., C.V., C.M.S.-R. and I.A. contributed to data curation. Q.Y., N.A. and

300 B.T.G. wrote the original draft. All authors contributed to reviewing and editing the draft.

301 References

- 302 [1] Claudia P. Arevalo et al. “A Multivalent Nucleoside-Modified mRNA Vaccine against All Known
303 Influenza Virus Subtypes”. In: *Science* 378.6622 (Nov. 2022), pp. 899–904. DOI: 10.1126/
304 science.abm0271.
- 305 [2] Nimalan Arinaminpathy et al. “A Global System for the next Generation of Vaccines”. In:
306 *Science* 376.6592 (Apr. 2022), pp. 462–464. DOI: 10.1126/science.abm8894.
- 307 [3] Nimalan Arinaminpathy et al. “Estimating Direct and Indirect Protective Effect of Influenza
308 Vaccination in the United States”. In: *American Journal of Epidemiology* 186.1 (2017), pp. 92–
309 100. ISSN: 14766256. DOI: 10.1093/aje/kwx037.
- 310 [4] Nimalan Arinaminpathy et al. “Impact of Cross-Protective Vaccines on Epidemiological and
311 Evolutionary Dynamics of Influenza”. In: *Proceedings of the National Academy of Sciences of
312 the United States of America* 109.8 (2012), pp. 3173–3177. ISSN: 00278424. DOI: 10.1073/pnas.
313 1113342109.
- 314 [5] Nimalan. Arinaminpathy et al. “Population Implications of the Deployment of Novel Universal
315 Vaccines against Epidemic and Pandemic Influenza”. In: *Journal of The Royal Society Interface*
316 17.164 (Mar. 2020), p. 20190879. DOI: 10.1098/rsif.2019.0879.
- 317 [6] Jacob Bock Axelsen et al. “Multiannual Forecasting of Seasonal Influenza Dynamics Reveals
318 Climatic and Evolutionary Drivers”. In: *Proceedings of the National Academy of Sciences* 111.26
319 (July 2014), pp. 9538–9542. DOI: 10.1073/pnas.1321656111. URL: [https://www.pnas.org/
320 doi/10.1073/pnas.1321656111](https://www.pnas.org/doi/10.1073/pnas.1321656111) (visited on 03/09/2023).
- 321 [7] Benjamin D. Dalziel et al. “Urbanization and Humidity Shape the Intensity of Influenza Epi-
322 demics in U.S. Cities”. In: *Science* 362.6410 (Oct. 5, 2018), pp. 75–79. DOI: 10.1126/science.
323 aat6030. URL: <https://www.science.org/doi/10.1126/science.aat6030> (visited on
324 08/29/2022).
- 325 [8] Xiangjun Du et al. “Evolution-Informed Forecasting of Seasonal Influenza A (H3N2)”. In:
326 *Science translational medicine* 9.413 (Oct. 2017), eaan5325. ISSN: 1946-6234. DOI: 10.1126/
327 scitranslmed.aan5325.
- 328 [9] Jonathan Dushoff et al. “Dynamical Resonance Can Account for Seasonality of Influenza Epi-
329 demics”. In: *Proceedings of the National Academy of Sciences* 101.48 (Nov. 30, 2004), pp. 16915–
330 16916. DOI: 10.1073/pnas.0407293101. URL: [https://www.pnas.org/doi/full/10.1073/
331 pnas.0407293101](https://www.pnas.org/doi/full/10.1073/pnas.0407293101) (visited on 08/14/2023).
- 332 [10] Neil M. Ferguson, Alison P. Galvani, and Robin M. Bush. “Ecological and Immunological Deter-
333 minants of Influenza Evolution”. In: *Nature* 422.6930 (Mar. 2003), pp. 428–433. ISSN: 1476-4687.
334 DOI: 10.1038/nature01509.

- 335 [11] *FluView*. URL: <https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>.
- 336 [12] Julia R. Gog and Bryan T. Grenfell. “Dynamics and Selection of Many-Strain Pathogens”. In:
337 *Proceedings of the National Academy of Sciences* 99.26 (Dec. 2002), pp. 17209–17214. ISSN:
338 0027-8424, 1091-6490. DOI: 10.1073/pnas.252512799.
- 339 [13] Katelyn M. Gostic et al. “Potent Protection against H5N1 and H7N9 Influenza via Childhood
340 Hemagglutinin Imprinting”. In: *Science* 354.6313 (Nov. 2016), pp. 722–726. ISSN: 0036-8075,
341 1095-9203. DOI: 10.1126/science.aag1322.
- 342 [14] Florian Krammer. “The Human Antibody Response to Influenza A Virus Infection and Vacci-
343 nation”. In: *Nature Reviews Immunology* 19.6 (June 2019), pp. 383–397. ISSN: 1474-1741. DOI:
344 10.1038/s41577-019-0143-6.
- 345 [15] Florian Krammer and Peter Palese. “Advances in the Development of Influenza Virus Vaccines”.
346 In: *Nature Reviews Drug Discovery* 14.3 (Mar. 2015), pp. 167–182. ISSN: 1474-1784. DOI: 10.
347 1038/nrd4529.
- 348 [16] Patrick J. Lillie et al. “Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza
349 Vaccine, MVA-NP+M1, in Humans”. In: *Clinical Infectious Diseases* 55.1 (July 2012), pp. 19–
350 25. ISSN: 1058-4838. DOI: 10.1093/cid/cis327.
- 351 [17] Raffael Nachbagauer et al. “A Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccine
352 Approach Induces Broad and Long-Lasting Immunity in a Randomized, Placebo-Controlled
353 Phase I Trial”. In: *Nature Medicine* 27.1 (Jan. 2021), pp. 106–114. ISSN: 1546-170X. DOI: 10.
354 1038/s41591-020-1118-7.
- 355 [18] Todd L. Parsons et al. “The Probability of Epidemic Burnout in the Stochastic SIR Model with
356 Demography”. Aug. 2023. URL: <https://hal.science/hal-04190409> (visited on 12/07/2023).
- 357 [19] Olivier Restif and Bryan T Grenfell. “Integrating life history and cross-immunity into the
358 evolutionary dynamics of pathogens”. In: *Proceedings of the Royal Society B: Biological Sciences*
359 273.1585 (Feb. 2006), pp. 409–416. ISSN: 0962-8452. DOI: 10.1098/rspb.2005.3335. URL:
360 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1560197/> (visited on 06/09/2021).
- 361 [20] Olivier Restif and Bryan T Grenfell. “Vaccination and the dynamics of immune evasion”. In:
362 *Journal of the Royal Society Interface* 4.12 (Feb. 2007), pp. 143–153. ISSN: 1742-5689. DOI: 10.
363 1098/rsif.2006.0167. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2358969/>
364 (visited on 06/09/2021).
- 365 [21] Rahul Subramanian et al. “Universal or Specific? A Modeling-Based Comparison of Broad-
366 Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines”. In: *PLoS Com-
367 putational Biology* 12.12 (2016), pp. 1–17. ISSN: 15537358. DOI: 10.1371/journal.pcbi.
368 1005204.
- 369 [22] Christine B. Turley et al. “Safety and Immunogenicity of a Recombinant M2e-Flagellin In-
370 fluenza Vaccine (STF2.4xM2e) in Healthy Adults”. In: *Vaccine* 29.32 (July 2011), pp. 5145–
371 5152. ISSN: 0264-410X. DOI: 10.1016/j.vaccine.2011.05.041.

- 372 [23] *U.S. Influenza Surveillance: Purpose and Methods* — CDC. Oct. 2022. URL: <https://www.cdc.gov/flu/weekly/overview.htm%5C#Outpatient>.
- 373
- 374 [24] Cécile Viboud et al. “Beyond Clinical Trials: Evolutionary and Epidemiological Considerations
375 for Development of a Universal Influenza Vaccine”. In: *PLOS Pathogens* 16.9 (Sept. 2020). Ed.
376 by Tom C. Hobman, e1008583. ISSN: 1553-7374. DOI: 10.1371/journal.ppat.1008583.
- 377 [25] Wan Yang, Eric H. Y. Lau, and Benjamin J. Cowling. “Dynamic Interactions of Influenza
378 Viruses in Hong Kong during 1998-2018”. In: *PLOS Computational Biology* 16.6 (June 2020),
379 e1007989. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.1007989.
- 380 [26] Wan Yang, Eric H. Y. Lau, and Benjamin J. Cowling. “Dynamic interactions of influenza
381 viruses in Hong Kong during 1998-2018”. en. In: *PLOS Computational Biology* 16.6 (June 2020).
382 Publisher: Public Library of Science, e1007989. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.
383 1007989. URL: <https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1007989> (visited on 06/08/2021).
- 384
- 385 [27] Wan Yang et al. “Forecasting Influenza Epidemics in Hong Kong”. In: *PLOS Computational
386 Biology* 11.7 (July 2015), e1004383. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.1004383.

387 S1 Supplementary information

388 The supplementary information includes:

- 389 • Dataset and code availability
- 390 • Ordinary differential equations of the model, Supplementary Tables S1-2
- 391 • Invasion analysis of a pandemic variant
- 392 • Supplementary Figures S1-11

393 S1.1 Dataset and codes

394 See R codes and data on our GitHub repository: <https://github.com/kikiyang/broadFluVacModel>

395 S1.2 Ordinary differential equations of the model

396 See Table S1 and S2 below for a description of all symbols in the model.

$$\left\{ \begin{array}{l}
 dS/dt = \mu - (\rho + \mu)S - \beta_1 S(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - \beta_2 S(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) + \sigma_1 R_1 + \sigma_2 R_2 + \sigma_V V \\
 dI_1/dt = \beta_1 S(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\gamma_1 + \mu)I_1 \\
 dR_1^T/dt = \gamma_1 I_1 + \sigma_{V_2} R_1^{V,T} - (\sigma_T + \mu + \rho_2)R_1^T \\
 dR_1/dt = \sigma_2 R_{1,2} + \sigma_T R_1^T + \sigma_{V_2} R_1^V - \beta_2(1 - \theta_1)R_1(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\mu + \sigma_1 + \rho_2)R_1 \\
 dI_{1,2}/dt = \beta_2(1 - \theta_1)R_1(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\mu + \gamma_2)I_{1,2} \\
 dI_2/dt = \beta_2 S(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\gamma_2 + \mu)I_2 \\
 dR_2^T/dt = \gamma_2 I_2 + \sigma_{V_1} R_2^{V,T} - (\mu + \sigma_T + \rho_1)R_2^T \\
 dR_2/dt = \sigma_1 R_{1,2} + \sigma_T R_2^T + \sigma_{V_1} R_2^V - \beta_1(1 - \theta_2)R_2(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\mu + \sigma_2 + \rho_1)R_2 \\
 dI_{2,1}/dt = \beta_1(1 - \theta_2)R_2(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\mu + \gamma_1)I_{2,1} \\
 dV/dt = \rho S + \sigma_1 R_1^V + \sigma_2 R_2^V - (\mu + \sigma_V)V - \beta_2(1 - \tau_1)V(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - \\
 \beta_1(1 - \tau_2)V(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) \\
 dI_1^V/dt = \beta_1(1 - \tau_2)V(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\gamma_1 + \mu)I_1^V \\
 dR_1^{V,T}/dt = \gamma_1 I_1^V + \rho_2 R_1^T - (\sigma_{V_2} + \sigma_T + \mu)R_1^{V,T} \\
 dR_1^V/dt = \sigma_2 R_{1,2}^V + \sigma_T R_1^{V,T} + \rho_2 R_1 - \beta_2(1 - \theta_1)(1 - \tau_1)R_1^V(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\sigma_1 + \sigma_{V_2} + \mu)R_1^V \\
 dI_{1,2}^V/dt = \beta_2(1 - \theta_1)(1 - \tau_1)R_1^V(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - \gamma_2 I_{1,2}^V - \mu I_{1,2}^V \\
 dI_2^V/dt = \beta_2(1 - \tau_1)V(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\gamma_2 + \mu)I_2^V \\
 dR_2^{V,T}/dt = \gamma_2 I_2^V + \rho_1 R_2^T - (\sigma_{V_1} + \sigma_T + \mu)R_2^{V,T} \\
 dR_2^V/dt = \sigma_1 R_{1,2}^V + \sigma_T R_2^{V,T} + \rho_1 R_2 - \beta_1(1 - \theta_2)(1 - \tau_2)R_2^V(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\sigma_2 + \sigma_{V_1} + \mu)R_2^V \\
 dI_{2,1}^V/dt = \beta_1(1 - \theta_2)(1 - \tau_2)R_2^V(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\gamma_1 + \mu)I_{2,1}^V \\
 dR_{1,2}^V/dt = \gamma_1 I_{2,1}^V + \gamma_2 I_{1,2}^V - (\sigma_1 + \sigma_2 + \mu)R_{1,2}^V \\
 dR_{1,2}/dt = \gamma_2 I_{1,2} + \gamma_1 I_{2,1} - (\mu + \sigma_1 + \sigma_2)R_{1,2}
 \end{array} \right. \tag{S1}$$

Table S1: Compartments in the model

Compartment	Definition
S	Susceptibles to both groups
V	Vaccinated
I_i	Primary infections by group i
$I_{i,j}$	Secondary infections by group j with a primary infection by group i
$I_{i,j}^V$	Infected individuals by strain j , who has been vaccinated (and had group i infection before)
$R_{i,j}^T$	Strain-transcending immune to both strains by primary infection by group i (and a secondary infection by group j)
$R_{i,j}^V$	Vaccinated and also immune to group i (and group j from infection)
$R_i^{V,T}$	Vaccinated and also strain-transcending immune to group i by previous infection by group i
R_i	Immune to group i
$R_{i,j}$	Immune to both group i and group j

Table S2: Parameters in the model

Parameter	Definition	Value	Source of the value
$R_0^{(i)}$	Basic reproductive number	1.44 (H1), 1.60 (H3)	[25]
β_i	Transmission rate of clade i	$\beta_i(t) = R_0^{(i)}(\gamma_i + \mu)(1 + a \cos(2\pi t))$, $\beta_0 = R_0(\gamma + \mu)$	/
a	amplitude of sinusoidal seasonal forcing function	0.04	See methods 2.2
γ_i	Recovery rate from infection of clade i	365/2.64 (H1), 365/3.03 (H3)	[25]
σ_T	Waning rate of strain-transcending immunity induced by infection	365/60	[10]
σ_i	Waning rate of immunity induced by natural infection of clade i	1/3.12 (H1), 1/2.28 (H3)	[25]
θ_i	Reduction in susceptibility of the other clade conferred by infection of clade i	/	See methods 2.2
σ_V	Waning rate of vaccinal immunity	$\sigma_V = k_2\sigma$	/
σ_{V_i}	Waning rate of immunity of the vaccine targeting clade i	$\sigma_{V_i} = k_2\sigma_i$	/
ρ	Vaccination rate	0-1	/
ρ_i	Vaccination rate of the vaccine targeting clade i	ρ	/
τ_i	Reduction in susceptibility of the other group conferred by vaccination against clade i	$\tau = k_1\theta$	/

397 S1.3 Invasion analysis of a pandemic variant

398 We used a similar method as in the previous study [20]. However, our model relaxes the assumption
 399 that two strains have the same reproductive ratio and other important epidemiological parameters.
 400 We first prepare a population where H3 clade is endemic in the presence of H3 vaccine and H1 clade
 401 is absent. We simulate the system for 600 years at semi-weekly time steps to bring H3 to endemic
 402 equilibrium, given by

$$\begin{cases} \hat{S} = \frac{\gamma_2 + \mu}{\beta_2} = \frac{1}{R_0^2} \\ \hat{I}_2 = \frac{\mu + \sigma_T}{\gamma_2} \hat{R}_2^T \\ \hat{R}_2^T = \frac{\mu + \sigma_2}{\sigma_T} \hat{R}_2 \\ \hat{V} = \frac{\rho}{\mu + \sigma_V} \hat{S} \end{cases} \quad (\text{S2})$$

403 where R_0^2 is the basic reproductive ratio of H3. The critical vaccination rate p_c makes the system at
 404 disease-free equilibrium, which gives the two following conditions:

$$\begin{cases} R_0^2 > 1 \\ p < p_c \equiv (R_0^2 - 1)(\sigma_V + \mu) \end{cases} \quad (\text{S3})$$

405 Hence, H3 clade is eliminated when $\sigma_V < \frac{1}{R_0^2 - 1} - \mu$ and $p < (R_0^2 - 1)(\sigma_V + \mu)$.

406 Next, we introduce a pandemic variant into the population at a very low frequency ($I_1 = 10^{-6}$).
 407 The initial invasion dynamics of the pandemic variant approximately follow the equations below.

$$\begin{cases} \frac{dI_1}{dt} = \beta_1 \hat{S}(I_1 + I_{2,1} + I_1^V) - (\gamma_1 + \mu)I_1 \\ \frac{dI_{2,1}}{dt} = \beta_1(1 - \theta_2) \hat{R}_2(I_1 + I_{2,1} + I_1^V) - (\mu + \gamma_1)I_{2,1} \\ \frac{dI_1^V}{dt} = \beta_1(1 - \tau_2) \hat{V}(I_1 + I_{2,1} + I_1^V) - (\gamma_1 + \mu)I_1^V \end{cases} \quad (\text{S4})$$

408 Let $X_2(t) = I_1(t) + I_{2,1}(t) + I_1^V(t)$, and assume that initially $X_2(t)$ approximately grows or decreases
 409 exponentially during a short time interval. This exponential behaviour can be written as Ce^{xt} , where
 410 C is a positive constant and x is the invasion rate of the pandemic variant. The equations S4 can be
 411 solved as:

$$\begin{cases} I_1(t) = \frac{\beta_1}{\gamma_1 + \mu + x} \hat{S} C e^{xt} + K_1 e^{-(\gamma_1 + \mu)t} \\ I_{2,1}(t) = K_{2,1} e^{-(\gamma_1 + \mu)t} + \frac{1 - \theta_2}{\gamma_1 + \mu + x} C \beta_1 \hat{R}_2 e^{xt} \\ I_1^V(t) = K_1^V e^{-(\gamma_1 + \mu)t} + \frac{1 - \tau_2}{\gamma_1 + \mu + x} C \beta_1 \hat{V} e^{xt} \end{cases} \quad (\text{S5})$$

412 where K_1 , $K_{2,1}$, K_1^V are three constants that depend on initial conditions. If $x > -(\gamma_1 + \mu)$,
 413 then the first term in each function rapidly becomes negligible. Since we initially assumed that
 414 $I_1(t) + I_{2,1}(t) + I_1^V(t) = Ce^{xt}$, then x must satisfy the following relation:

$$f(x) \equiv \frac{\beta_1}{x + \gamma_1 + \mu} (\hat{S} + (1 - \theta_2) \hat{R}_2 + (1 - \tau_2) \hat{V}) = 1. \quad (\text{S6})$$

415 $f(x)$ is a continuous, decreasing function over $(-(\gamma_1 + \mu), \infty)$. If cross-immunity is perfect, i.e.
 416 $\theta_2 = \tau_2 = 1$, then $f(x) = \frac{\beta_1(\gamma_2 + \mu)}{\beta_2(x + \gamma_1 + \mu)} = 1$, therefore $x = \beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1})$ is a solution for (S6).
 417 Otherwise, $f(\beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1})) > 1$, so $f(x)$ admits a unique solution $x > \beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1})$. When $R_0^2 < R_0^1$,
 418 i.e., the basic reproductive ratio of the endemic strain is smaller than the invading variant, $x > 0$,
 419 i.e., the pandemic always emerges. Otherwise, $\beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1}) < 0$, and therefore x could be negative

420 or positive. In our case, where $\theta_2 = 0$, the unique solution can be written as below.

$$x = \beta_1(\hat{S} + \hat{R}_2 + (1 - \tau_2)\hat{V}) - (\gamma_1 + \mu) \quad (S7)$$

421 We can see that the vaccine characteristics (σ_V , τ_2 and ρ) and their relationship with the pathogen
 422 epidemiological parameters decide if pandemic emergence could be successful.

423 S1.4 Figures




Figure S1: Sensitivity test for initial conditions. The initial condition 1 assumes susceptible population is 89.9%, H1 infection is 0.01% and H3 infection is 0.1%. The initial condition 2 assumes the susceptibles are 89.9%, H1 infection is 0.1% and H3 infection is 0.01%. Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *strengths* (columns, defined as $k_1 = \frac{\tau_i}{\theta_i}$), with changes of vaccination rate (%) per week (x axis). The results are calibrated with the best-fitting parameters ($\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$). Other parameters are the same as in 2.




Figure S2: Sensitivity test for initial conditions. Parameters are the same as in S1. Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity durations (columns, defined as $k_2 = \frac{\sigma_i}{\sigma_V}$), with changes of vaccination rate (%) per week (x axis).




Figure S3: Weekly incidence of human influenza H1N1 (in red) and H3N2 (in blue) in the United States. The grey area is pandemic seasons from 2009-07-01 to 2011-07-01; they are excluded in the model calibration.




Figure S4: The optimization metric distribution across the parameter space of a , θ_1 and θ_2 . Each grid represents a combination of the parameters, the colour of which shows the sum of the absolute distance between simulation and data [11] of three summary statistics, including I) correlation between H1 and H3 seasonal incidence, II) coefficient of variation of H1 (and H3) seasonal incidence, III) auto-correlation of H1 (and H3) seasonal incidence.




Figure S5: The distribution of the optimization metric (< 3) across the parameter space of a , θ_1 and θ_2 . Each grid represents a combination of the parameters, the colour of which shows the sum of the absolute distance between simulation and data [11] of three summary statistics, including I) correlation between H1 and H3 seasonal incidence, II) coefficient of variation of H1 (and H3) seasonal incidence, III) auto-correlation of H1 (and H3) seasonal incidence.




Figure S6: Occurrence counts of the same parameter sets of θ_1 and θ_2 with different a that gives optimization metric value smaller than 3.




Figure S7: Histogram of correlation between H1 and H3 seasonal incidence (left-top panel), auto-correlation of H1 (and H3) incidence (right-top panel) and coefficient of variation of H1 (and H3) incidence (left-bottom panel) of every 12-yr period of the 2000-year simulation with first 800 years as burn-in, using $\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$ as the parameters. Dashed lines show the metric values in the incidence data. Blue and red colours represent H3 and H1 respectively.




Figure S8: Histogram of correlation between H1 and H3 seasonal incidence (left-top panel), auto-correlation of H1 (and H3) incidence (right-top panel) and coefficient of variation of H1 (and H3) incidence (left-bottom panel) of every 12-yr period of the 2000-year simulation with first 800 years as burn-in, using $\theta_1 = 0.55, \theta_2 = 0.35, a = 0.04$ as the parameters. Dashed lines show the metric values in the incidence data. Blue and red colours represent H3 and H1 respectively.




Figure S9: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *strengths* (columns, defined as $k_1 = \frac{\tau_i}{\theta_i}$), with changes of vaccination rate (%) per week (x axis). The results are calibrated with the moderate-fitting parameters ($\theta_1 = 0.55, \theta_2 = 0.35, a = 0.04$). Other parameters are the same as in 2.




Figure S10: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *durations* (columns, defined as $k_2 = \frac{\sigma_i}{\sigma_V}$), with changes of vaccination rate (%) per week (x axis). The parameters are the same as in S9.




Figure S11: Persistence of the endemic variant 5 years after its emergence, measured by trough depth of its incidence ((the minimal incidence), under vaccination of different immunity strength (y axis), duration (row) and vaccination rate ρ (%) per week (x axis), with different basic reproduction number R_0^1 (column). The grey area is when the endemic strain fails to persist. The black curve indicate the transition between persistence and failure in the persistence of the endemic strain. Other parameters are same as those in Figure 4.




Figure S12: Deterministic trajectories after the pandemic strain (at the incidence of 10^{-6}) invades the endemic equilibrium of H3. Line types represent weak (20%), middle (40%), and strong (80%) susceptibility reduction against the pandemic strain (τ_2) by the vaccine. $R_0^2 = 3.2$, $1/\sigma_V = 16(\text{yr})$, $\rho = 1.73\%$ per week. Other parameters are as in Figure 4.